Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 19 - Drugs for skeletal disorders
Patents for A61P 19 - Drugs for skeletal disorders (81,981)
05/2003
05/15/2003CA2465981A1 Antigen arrays comprising rankl for treatment of bone disease
05/15/2003CA2465945A1 Nutritional supplements and methods for prevention, reduction and treatment of radiation injury
05/15/2003CA2465894A1 Method for treating or preventing inflammatory diseases
05/15/2003CA2465862A1 Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism
05/15/2003CA2465695A1 2-amino-thiazoline derivatives and their use as inhibitors of inducible no-synthase
05/15/2003CA2465499A1 Compositions and methods for treating osteoporosis
05/15/2003CA2465416A1 Amine salts of an integrin receptor antagonist
05/15/2003CA2465239A1 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
05/15/2003CA2464765A1 Type 2 cytokine receptor and nucleic acids encoding same
05/15/2003CA2464717A1 Compounds and methods for treating transplant rejection
05/15/2003CA2464614A1 Pharmaceutical composition comprising factor vii polypeptides and pai-1 polypeptides
05/15/2003CA2459745A1 Imidazole-4-carboxamide derivatives, preparation and use thereof for treatment of obesity
05/14/2003EP1310571A2 A Method of detecting and/or identifying adeno-associated virus (AVV) sequences and isolating novel sequences identified thereby
05/14/2003EP1310554A1 Polypeptides controlling phosphoric acid metabolism, calcium metabolism, calcification and vitamin d metabolism and dnas encoding the same
05/14/2003EP1310509A2 Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
05/14/2003EP1310494A1 PPAR (delta) ACTIVATORS
05/14/2003EP1310493A1 N-adamantylalkyl benzamide derivates as p2x7-receptor antagonists
05/14/2003EP1310484A1 1-methyl-20-epivitamin d derivative
05/14/2003EP1310262A1 Topical composition having undifferentiated plant seed cells and method for using same
05/14/2003EP1310259A2 Formulation comprising a biphosphonate and an absorption enhancing agent for the treatment of osteoporosis
05/14/2003EP1309721A2 Modulating multiple lineage kinase proteins
05/14/2003EP1309704A2 Regulation of human membrane-type serine protease
05/14/2003EP1309697A2 Regulation of human 11 beta-hydroxysteroid dehydrogenase 1-like enzyme
05/14/2003EP1309684A2 Polynucleotides and polypeptides encoded thereby
05/14/2003EP1309616A1 Integrin binding motif containing peptides and methods of treating skeletal diseases
05/14/2003EP1309609A2 Lactam compounds and their use as inhibitors of serine proteases and method
05/14/2003EP1309596A2 Heterocyclic compounds useful as inhibitors of tyrosine kinases
05/14/2003EP1309592A2 Substituted pyrazoles
05/14/2003EP1309591A2 Substituted pyrazoles
05/14/2003EP1309589A2 Urea compounds and methods of uses
05/14/2003EP1309587A1 Cinnoline compounds
05/14/2003EP1309575A1 Biphenyl derivatives and their use as ppar-gamma receptor activators
05/14/2003EP1309571A1 Non-steroidal inflammation inhibitors
05/14/2003EP1309563A1 Heterocyclic-hydroxyimino-fluorenes and their use for inhibiting protein kinases
05/14/2003EP1309560A1 Pyridine derivatives as inhibitors of p38
05/14/2003EP1309552A1 Compounds and inhibitors of phospholipases
05/14/2003EP1309373A2 Method and composition for altering a t cell mediated pathology
05/14/2003EP1309355A1 Peptide and peptide mimetic conjugates with integrin-inhibitor properties
05/14/2003EP1309346A2 Treatment of hiv-1 infection and inflammatory disease using cyclophilin receptor antagonists
05/14/2003EP1309326A1 A therapeutic agent of osteoporosis comprising an active ingredient of quercetin derivatives
05/14/2003EP1309316A2 Oral fast-melt dosage form of a cyclooxygenase-2 inhibitor
05/14/2003EP1309315A2 Rapidly disintegrating oral formulation of a cyclooxygenase-2 inhibitor
05/14/2003EP1240162B1 Novel derivatives of 3-imino-1,2-dithioles, method for producing them and pharmaceutical compositions containing the same
05/14/2003EP1102746B1 Substituted phenylamidines with antithrombotic action
05/14/2003EP1021194B1 New improved formulation for treatment of osteoporosis
05/14/2003CN1418215A Substituted beta-carbolines with IKB-kinase inhibiting activity
05/14/2003CN1418210A Carbocyclik side chain containing, N-substituted Metalloprotease inhibitors
05/14/2003CN1418209A Carbocyclic side chain containing metalloprotease inhibitors
05/14/2003CN1418199A Pyrimidine-4-one derivatives as LDL-PLA2 inhibitors
05/14/2003CN1418197A Piperidine and piperazine substituted N-hydroxyformamides as inhibitors of metalloproteinases
05/14/2003CN1418194A Amide compounds and use thereof
05/14/2003CN1418193A heterocyclic side chain containing metalloprotease inbibitors
05/14/2003CN1418191A Novel thiourea derivatives and the pharmaceutical compositions containing thd same
05/14/2003CN1418190A N-deacetylthiocolchicine derivatives and pharmaceutical compositions containing them
05/14/2003CN1418187A Carboxylic acid derivatives as IP antagonists
05/14/2003CN1418185A Aniline-derived ligands for thyroid receptor
05/14/2003CN1418105A Use of MIA in immunotherapy
05/14/2003CN1418103A Polysaccharidic esters of N-derivatives of glutamic acid
05/14/2003CN1418102A 激素替代疗法 Hormone replacement therapy
05/14/2003CN1418096A IL-8 receptor antagonists
05/14/2003CN1416873A Medicine composition for treating osteoporosis and its prepn
05/14/2003CN1416837A Bone Bi-syndrome treating pill
05/14/2003CN1416833A Kuasuning capsule for treating ischemic femoral head necrosis
05/14/2003CN1416823A Medicine composition for treating osteoporosis
05/14/2003CN1416806A Local composition with undifferentiated plant seed cell and ifs usage
05/14/2003CN1416728A Health food capable of increasing bone density and delaying senility and its production process
05/14/2003CN1108170C Buffering liquid for staphylococcus Aureus Injection and stephylococcus Aureus Injection with buffering liquid
05/13/2003US6562988 16-HETE (16-hydroxyeicosatetraenoic acid) analogues such as the methanesulfonamide ester (-CO-NH-SO2-CH3); inhibiting neutrophil adhesion and neutrophil aggregation; treating stroke, inflammatory diseases
05/13/2003US6562963 Coupling using organosilicon compound
05/13/2003US6562851 Antiinflammatory and antiasthmatic agents; inhibitors of alpha4 beta1 mediated cell adhesion
05/13/2003US6562849 Amine compound or pharmacologically acceptable salt thereof. These compounds are useful in the treatment and/or prophylaxis of diseases such as diabetes, hyperlipemia, arteriosclerosis, cancer, etc.
05/13/2003US6562843 For treating disorders ameliorated by a reduction in TNF-alpha production and/or p38 activity, and are therefore useful for treating inflammatory disorders such as rheumatoid arthritis, as well as AIDS-related disorders
05/13/2003US6562837 Use of tetrahydroisoquinoline compounds for the treatment of septicemia
05/13/2003US6562831 Inhibitors of the mitotic kinesin KSP and are useful in the treatment of cellular proliferative diseases
05/13/2003US6562825 For treating inflammatory disease including asthma and allergic diseases, as well as autoimmune pathologies
05/13/2003US6562821 For treating arthritis and related disorders, and for treating diseases associated with altered mitochondrial function
05/13/2003US6562811 Pyridine derivatives
05/13/2003US6562613 Recombinant C-proteinase and processes, methods and uses thereof
05/13/2003CA2127876C Imidazole derivatives and their use as cytokine inhibitors
05/13/2003CA2096933C Compounds and compositions which inhibit bone resorption
05/10/2003WO2002036120A1 Use of stimulators of soluble guanylate cyclase for treating osteoporosis
05/10/2003CA2427551A1 Use of stimulators of soluble guanylate cyclase for treating osteoporosis
05/08/2003WO2003038123A2 Methods to treat diabetes and related conditions based on polymorphisms in the tcf1 gene
05/08/2003WO2003038110A2 7118, a human arginine n-methyltransferase family member and uses therefor
05/08/2003WO2003038095A2 Isolated peptide of the hepatocyte growth factor and its variants, preparation method and therapeutic use as anti-angiogenic agents
05/08/2003WO2003038088A1 Molecular diagnosis method for multiple myeloma
05/08/2003WO2003038058A2 Surfactant protein d for the prevention and diagnosis of pulmonary emphysema
05/08/2003WO2003038043A2 Combinations of dr5 antibody and other therapeutic agents
05/08/2003WO2003037916A2 Linear basic compounds having nk-2 antagonist activity and formulations thereof
05/08/2003WO2003037892A1 Compounds useful as reversible inhibitors of cysteine proteases
05/08/2003WO2003037874A1 An efficient synthesis of 5-heteroatom-containing-pyrazoles
05/08/2003WO2003037852A1 Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors
05/08/2003WO2003037433A1 Co-cycloalkyl 17-heteroaryl prostaglandin e2 analogs as ep2-receptor agonists
05/08/2003WO2003037432A1 Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors
05/08/2003WO2003037377A1 Preventives/remedies for proliferative organ diseases, chronic arthritic diseases, hypertrophic scar or keloid
05/08/2003WO2003037362A2 Mnk kinase homologous proteins involved in the regulation of energy homeostasis and organelle metabolism
05/08/2003WO2003037352A1 1-phenyl-5-n-heterocyclyl-pyrazoles as cyclooxygenase inhibitors for the treatment of inflammation associated disorders
05/08/2003WO2003037351A1 Heterocyclo-alkylsulfonyl pyrazoles and their use as cox-2 inhibitors
05/08/2003WO2003037349A1 Type 4 phosphodiesterase inhibitors and uses thereof
05/08/2003WO2003037347A1 Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
1 ... 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 ... 820